ClinicalTrials.gg
CompletedNCT04973111Updated Mar 28, 2025

A Study to Assess CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose

A Phase 1 interventional study of CT-868 as SC Injection and Placebo as SC Injection in Diabetes, sponsored by Carmot Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-28.

Sponsored by Carmot Therapeutics, Inc. (part of Hoffmann-La Roche) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Apr 2022, 4 years 7 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Diabetes Mellitus by Hoffmann-La Roche — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus · Hoffmann-La Roche.

Enrollment
9th of 10
32 · median 180
Started
2021
with 1 other
Phase 1
3 of 12
none open now
Registered
12th of 12
by date

Among the 12 studies in Diabetes Mellitus by Hoffmann-La Roche, this one is the 9th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2021, is one of 3 in phase 1, and was the 12th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

None of the 12 studies in Diabetes Mellitus by Hoffmann-La Roche is open now. The open studies under Diabetes Mellitus, anywhere →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Diabetes Mellitus by Hoffmann-La Roche as a file.
02

Study summary

A Study to Assess the Effect of CT-868 and the Relationship Between Insulin Secretory Response and Ambient Blood Glucose in Obese Male Subjects and Subjects with T2DM.

03

Conditions studied

  • Diabetes

Keywords

  • Diabetes Mellitus
  • Diabetes Mellitus, Type 2
  • Overweight
  • Metabolic Diseases
  • Body Weight
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Part 1: Obese Otherwise Healthy Males
  • Part 2: Males or Females with T2D
  • Part 1: 30.0-35.0, inclusive
  • Part 2: BMI 27.0-45.0, inclusive
  • 18-65 years old, inclusive
  • Stable body weight for 2 months

Exclusion criteria

Exclusion Criteria:

  • Significant medical history
  • Uncontrolled hypertension
  • History of
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    CT-868

    SC dose of CT-868 Intervention: Drug: CT-868

    Drug: CT-868 as SC Injection

  • Placebo comparator
    Placebo

    SC dose of placebo matching CT-868 dose Intervention: Drug: Placebo

    Drug: Placebo as SC Injection

  • Active comparator
    Active Comparator

    SC dose of Active Comparator Intervention: Drug: Active Comparator

    Drug: Active Comparator as SC Injection

Interventions

  • DrugCT-868Studies of CT-868CT-868 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    CT-868

  • DrugPlacebo as SC Injection

    Placebo

  • DrugActive Comparator as SC Injection

    Active Comparator

06

What researchers measure

Primary outcomes

  1. Change in insulin secretion rate and ambient glucose levels

    Time frame: Baseline up to 4 days

Secondary outcomes

  1. Change in blood insulin levels at each level of glucose infusion

    Time frame: Baseline up to 4 days

  2. Change in blood glucose levels at each level of glucose infusion

    Time frame: Baseline up to 4 days

07

Study locations

1 site
  • Carmot Clinical Research Unit 101
    Chula Vista, California 91911, United States
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2021 to primary completion in Apr 2022, 9 months.

Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's 9 months is above that.

Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2021
First posted
Jul 22, 2021
StartActual
Jul 16, 2021
Primary completionActual
Apr 22, 2022
CompletionActual
Apr 22, 2022
Last update
Mar 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04973111
Responsible party
Sponsor
First posted
Jul 22, 2021
Start date
Jul 16, 2021
Primary completion
Apr 22, 2022
Completion
Apr 22, 2022
Last update
Mar 28, 2025

Study contacts

Clinical Trials
study director · Carmot Therapeutics, Inc., a member of the Roche Group

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CT-868

Start the discussion